Genmab A/S (NASDAQ:GMAB) Upgraded by JPMorgan Chase & Co. to “Overweight”
JPMorgan Chase & Co. upgraded shares of Genmab A/S (NASDAQ:GMAB) from a neutral rating to an overweight rating in a research note published on Thursday, BenzingaRatingsTable reports. They currently have $23.00 price target on the stock.
Several other equities research analysts also recently issued reports on GMAB. Royal Bank of Canada assumed coverage on shares of Genmab A/S in a research note on Monday, August 12th. They set an outperform rating and a $23.00 price objective for the company. Morgan Stanley began coverage on shares of Genmab A/S in a research note on Monday, August 12th. They issued an overweight rating for the company. HC Wainwright restated a buy rating on shares of Genmab A/S in a research note on Monday, August 26th. Finally, Guggenheim began coverage on shares of Genmab A/S in a research note on Monday, August 12th. They issued a buy rating for the company. Six investment analysts have rated the stock with a buy rating, The stock presently has an average rating of Buy and a consensus target price of $23.00.
GMAB traded down $0.31 during trading on Thursday, hitting $20.06. 351,817 shares of the company’s stock were exchanged, compared to its average volume of 195,057. Genmab A/S has a 1 year low of $12.10 and a 1 year high of $21.45.
Genmab A/S Company Profile
Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL).
Featured Story: Is it Safe to Invest in Commodities?
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.